Venation was founded with a goal to be unlike any other company out there. We are striving to provide clients with a one of a kind product. Our treatments are provided to improve wellness and provide your body with key nutrients that one simply cannot get from diet alone. Our clinics are different from all the drip bars out there. We want you to feel safe and welcome whether alone or in groups. An IV drip consisting of customized or pre-formulated vitamins and minerals directly into the bloodstream. This allows up to 100% absorption of vitamins, minerals, amino acids and antioxidants, in comparison to an average of 30% with oral supplements. Bypassing the digestive system allows the nutrients to enter at a cellular level. This therapy can be used to maintain a healthy lifestyle or to help with chronic conditions such as inflammation, pain, and malnutrition. Vitamin IV provides hydration and proper nutrition. This can aid in things like energy, mood, immunity, muscle recovery and sleep. You can visit Venations website Here The rest is here: Stem Cell Therapy - Premier Regenerative Stem Cell … Continue reading →

Current Patients 480.998.7999 New Patients 480.400.8506 Dr. Todd Malan is considered one of the true pioneers of fat derived stem cell therapies in the USA. In October of 2009, Dr. Todd Malan was the first U.S. physician to utilize adipose or fat derived stem cells for soft tissue reconstruction. He has described his techniques and experience as an author in two medical textbooks as well as having presented at dozens of stem cell conferences worldwide. Mycal's Story: Knee Conditions Cara's Story: Hereditary Inclusion Body Myopathy Dale's Story: No more Pain Medications "I wanted to thank you all so much for making every step of my procedure pleasant and easy. Your dedication to excellence shines through." - Jen R, Minnesota "We appreciate your excellence and expertise. You treated us like family and have given us hope. I am walking without limping." - Doug J, New Mexico "I just wanted you to know how enormously grateful I am to all of you there. The stem cell treatment had a profound impact on my life! I can't thank you enough." - Sean H, Arizona "I can run my finger along the area of the achilles tendon where the damaged fibers were and feel … Continue reading →

Cell Medica is buying Catapult Therapy TCR and the firm's gene-modified WT1-TCR (Wilms' tumor 1 proteinT-cell receptor) T-cell therapy candidate. The treatment is currently in Phase I/II development for the potential treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Catapult Therapy TCR is a special purpose vehicle established by The Cell and Gene Therapy Catapult (CGT Catapult), UCL Business (UCLB), and Imperial lnnovations to develop the WT1-TCR T-cell therapy, which was originally discovered by researchers at University College London (UCL) and Imperial College London. Financial details of the acquisition were not disclosed. Cell Medical says it plans to apply its Dominant TCR platform to generate a more effective WT1-TCR product that could also feasibly be used to treat challenging solid tumors, including mesothelioma and ovarian cancer. The firm acquired the Dominant TCR technology from UCLB in 2016. London, U.K.-based Cell Medica and CGT Catapult will carry out further development of the next generation of T cells, and manufacturing process, at the latters recently built large-scale cell and gene therapy manufacturing center at the Stevenage BioScience Catalyst, U.K.A Phase I/II study with the enhanced Dominant WT1-TCR candidate is projected to start during late 2018. The acquisition of the WT1-TCR … Continue reading →

While Flagship Pioneering was unwrapping a huge $120 million round for Rubius this morning, the busy venture group also launched a biotech on a mission to create a new type of encapsulated cell therapy. Turning to two scientific founders MITs Daniel Anderson and the prolific Robert Langer the discovery group at Flagship has been working on permeable biomaterials that are designed to implant cells in tissue to deliver proteins in a sustained fashion, without triggering fibrosis. Paul Wotton, CEO, Sigilon Researchers have been refining this tech in Flagships VentureLabs for the past two years, and now they are pursuing it at Sigilon Therapeutics with a $23.5 million A round. Imagine the potential of a living therapeutic that could be implanted in the body and manufacture and release therapeutic proteins at steady levels for long periods of time, avoiding the critical limitations of intermittent infusion required with current therapies, said CEO Paul Wotton. Flagship has pulled together another veteran team for this new player. Wotton ran Ocata until it was bought out by Astellas. This rest of the team includes chief technology officer David Peritt, a Pfizer vet, and chief strategyofficer and head of operations Devyn Smith, who was previously head … Continue reading →

Making uses of the advances in cell therapy, Apollo Hospitals on Tuesday announced partnership with RMS REGROW, to offer new regenerative medicine cell therapy products that will be a boon for patients suffering from bone and cartilage damage. The two products- Ossron and Chondron, will address unmet clinical needs in the orthopaedic market with respect to sports injuries, accidents and alternate to hip replacements and knee replacements for a young arthritic knee. In an exclusive tie up between Apollo Hospitals and RMS Regrow, the treatment therapy will be made available across all Apollo Hospitals, Apollo Spectra Hospitals and Apollo clinics in India. Through several clinical trials and evaluation studies that spanned around 8 years, the company has achieved the market authorization for the two cell therapy products. Doctors will be trained in using the products by conducting live surgical workshops and conferences etc. both nationally and internationally. Apollo Group wants to encourage research and innovation within India for the people of India. Our association with RMS Regrow is a step to inspire talent in India to further the advancement in developing innovative healthcare treatments to reduce the growing disease burden in India, said Dr Prathap C Reddy, founder-chairman, Apollo Hospitals. … Continue reading →

ImmunoCellular Therapeutics Ltd has halted a Phase III trial of its brain cancer cell therapy ICT-107 due to a lack of funds and is looking for a buyer or partner for the programme. The Los Angeles, US-based biotech announced the move on June 21, explaining it is unable at this time to secure sufficient additional financial resources to complete the phase III registration trial of ICT-107. ImmunoCellular said it is looking for a partner or buyer for the programme adding that the suspension of the phase III registration trial of ICT-107 is expected to reduce the amount of cash used in the Companys operations. ICT-107 is a dendritic cell (DC) vaccine designed to activate a patients immune system to target six different antigens associated with glioblastoma multiforme, a form of brain cancer. ThePhase III trial is being conducted at sites in the US, Austria and Canada. The halt comes weeks after ImmunoCellular Therapeutics signalled its intention to raise funds to allow it to continue the study. R&D costs According to a first quarter filing ,ImmunoCellular Therapeutics has cash reserves of $5.3m (4.68m), which is just under half of what it had in reserve this time last year. The document also … Continue reading →

Dive Brief: Even more than traditional drug development, manufacturing is a crucial step in the development of complex therapeutics like cell therapies. As the field evolves, it will likely be a difference maker between success and setback. Such focus on production and logistics can be see in the attention paid to the processes set up by the more advanced CAR-T developers like Kite Pharma, Novartis and Juno Therapeutics. With this deal, Cell Medica has seized on an opportunity to gain access to an existing GMP facility, taking a short cut to support further development and potential commercialization of the WT1-TCR therapy. More cell therapy products might also be produced at the site in the future, Cell Medica said. Catapult Therapy TCR was created by CGT Catapult, UCL Business and Imperial Innovations the technology transfer arms of University College London and Imperial College, London in order to develop the WT1-TCR cell therapy. By acquiring Catapult Therapy TCR, Cell Medica can also integrate WT1-TCR cell therapy into its Dominant TCR platform technology. This has potential to improve efficacy, Cell Medica believes, and to expand use of the therapeutic from its existing focus on blood cancers to hard-to-treat solid tumors such as mesothelioma … Continue reading →